Precidian ETFs Trust GSK plc (GSKH)

Key Updates

GSKH declined 2.59% to $70.83 since the April 30 report, extending the downtrend to four consecutive reporting periods and marking a cumulative 11.90% decline over the past month. The sell-off accelerated despite GSK plc's strong Q1 earnings beat and positive clinical trial data for Mo-Rez, suggesting investors remain focused on the company's unchanged full-year guidance and concerns about the drug pipeline's ability to offset upcoming patent expirations. The stock has now retraced most of its YTD gains, trading just 3.85% above year-end levels, while the investment thesis faces increased pressure from the widening gap between current performance and the company's ambitious 2031 revenue targets.

Current Trend

GSKH remains in a pronounced downtrend, declining 11.90% over the past month and 6.08% in the past five days alone. The YTD performance of +3.85% represents a significant deterioration from previous reporting periods, with the stock breaking through multiple support levels at $76, $72, and now testing the $70 threshold. The 6-month performance of +4.44% demonstrates the recent acceleration of selling pressure, as nearly all medium-term gains have been eliminated in April's decline. The stock is trading at its lowest level since early January, with momentum indicators pointing to continued weakness absent a catalyst to reverse sentiment.

Investment Thesis

The investment thesis centers on GSK's transformation under CEO Luke Miels through aggressive pipeline acceleration and strategic acquisitions to address historical underinvestment in R&D. The company targets £40 billion in revenue by 2031, driven by specialty medicines (projected low double-digit growth), oncology expansion via Mo-Rez (potential £2 billion blockbuster), and recent acquisitions including RAPT Therapeutics ($2.2 billion) and 35Pharma ($950 million). However, the thesis faces critical near-term risks from patent expirations on dolutegravir-based HIV drugs beginning in 2028, which threaten approximately 20% of current revenue, and potential US policy changes affecting vaccine demand under the Kennedy administration.

Thesis Status

The investment thesis is encountering significant headwinds despite operational execution meeting expectations. While GSK delivered Q1 results that beat estimates with 5% revenue growth and 10% core operating profit growth, driven by specialty medicines and record Shingrix sales, the market's negative reaction reflects skepticism about the company's ability to bridge the gap between current performance (1.7% annual growth since 2006) and ambitious targets. Management's decision to reiterate rather than upgrade full-year guidance disappointed investors, suggesting Q1 strength may not be sustainable. The Mo-Rez clinical trial success provides validation for the oncology strategy, but the five simultaneous late-stage trials represent significant execution risk and capital deployment before revenue materialization. The 2028 patent cliff looms as a critical test of whether the pipeline can offset structural revenue losses.

Key Drivers

GSK's Q1 earnings beat expectations with EPS of 46.5 pence versus 43.2 pence consensus, driven by specialty medicines including Jemperli for endometrial cancer and Apretude for HIV prevention, alongside record Shingrix vaccine sales. However, both GSK and AstraZeneca experienced share price declines of 1.4-2.5% following their earnings reports due to unchanged full-year guidance, indicating investors require evidence of accelerating growth rather than steady performance. The company announced promising early-stage results for Mo-Rez with 62% response rates in ovarian cancer and 67% in endometrial cancer patients, positioning the drug as a potential blockbuster with peak sales exceeding £2 billion. The company faces patent expirations on dolutegravir-based drugs beginning in 2028 that will impact approximately one-fifth of revenue, creating urgency for pipeline advancement. Additionally, GSK received marketing approvals from the European Commission and China for depemokimab, the first ultra-long-acting biologic with twice-yearly dosing, expanding its commercial footprint in key markets.

Technical Analysis

GSKH exhibits severe technical deterioration with consecutive lower highs and lower lows across all timeframes. The stock broke decisively below the $76 support level identified in previous reports, accelerated through $72, and is now testing critical support at $70. The one-month decline of 11.90% represents the steepest drawdown in the recent trading history, with selling pressure intensifying rather than abating. The 5-day decline of 6.08% and 1-day decline of 1.00% demonstrate continued momentum to the downside. Volume patterns suggest institutional distribution rather than retail panic, as the selling has been persistent and methodical. The stock is trading below all major moving averages, with the YTD gain of just 3.85% indicating vulnerability to testing year-end levels around $68. Resistance has now formed at $72-$73, with the $76 level representing a significant overhead barrier. Without a fundamental catalyst, the technical picture suggests further downside risk toward $68-$65 before a sustainable bottom forms.

Bull Case

• Mo-Rez demonstrated exceptional efficacy with 62% response rates in chemotherapy-resistant ovarian cancer and 67% in endometrial cancer, positioning it as a potential £2 billion blockbuster that could materially impact GSK's 2031 revenue target of £40 billion
• Q1 earnings beat estimates with specialty medicines projected to deliver low double-digit percentage growth this year, driven by Jemperli, Apretude, and record Shingrix sales, demonstrating the commercial strength of GSK's current portfolio
• Depemokimab received marketing approvals from the European Commission and China following earlier approvals in the US, Japan, and UK, establishing the first ultra-long-acting biologic with twice-yearly dosing across major global markets
• The stock has risen approximately 50% since CEO Luke Miels' appointment announcement in September, with five simultaneous late-stage trials for Mo-Rez representing an aggressive strategy that mirrors successful approaches by competitors like AstraZeneca
• GSK's acquisitions of RAPT Therapeutics for $2.2 billion and 35Pharma for $950 million strengthen its respiratory and immunology portfolio, with management signaling continued focus on proven-science drug developers with competitive advantages in existing commercial areas

Bear Case

• Patent expirations on dolutegravir-based drugs beginning in 2028 will threaten approximately one-fifth of GSK's revenue, creating a structural headwind that requires successful pipeline execution to offset, while the company has grown revenue at only 1.7% annually since 2006 compared to AstraZeneca's 4.2%
• GSK and AstraZeneca both experienced share price declines of 1.4-2.5% despite beating Q1 earnings expectations, as management reiterated rather than upgraded full-year guidance, signaling investor skepticism about growth sustainability
• GSK's vaccine business faces significant headwinds from potential US policy changes under the Kennedy administration, which could materially impact demand for vaccines that represent a substantial portion of the company's revenue base
• CEO Luke Miels faces persistent investor concerns about the company's drug pipeline despite oncology performing well, with weaker consumer demand impacting related health companies like Haleon, whose shares fell 1.2% due to reduced cold and flu medicine sales
• The five simultaneous late-stage trials for Mo-Rez represent significant execution risk and capital deployment years before potential revenue generation, with GSK's historical weakness in oncology following its 2015 exit raising questions about the company's ability to compete effectively in this space